Mosaic licenses 2 clinical stage tumor drugs from Otsuka`s Astex
24 Apr 2025 //
FIERCE BIOTECH
Mosaic Closes $28m Series A Funding and Appoints Brian Gladsden as CEO
04 Apr 2023 //
BUSINESSWIRE
24 Apr 2025 //
FIERCE BIOTECH
04 Apr 2023 //
BUSINESSWIRE